-transparent.png){kind=logo}
The purpose of the present report is to review the available pharmacokinetic information on amiodarone with an emphasis on our own experience in monitoring serum amiodarone concentrations. We have found that 400 mg should be the maximal maintenance dose; if that treatment fails, careful addition of other antiarrhythmic agents is preferable over an increase in amiodarone dosage. Serum concentrations below 2.5 mg/L will significantly improve amiodarone's benefit-to-risk ratio.
Related Publications
H H Rotmensch, and
B N Swanson, and
A J Greenspon, and
D Shoshani, and
A M Greenspan
November 1989,
The American journal of cardiology,
H H Rotmensch, and
B N Swanson, and
A J Greenspon, and
D Shoshani, and
A M Greenspan
October 2016,
Statistics in medicine,
H H Rotmensch, and
B N Swanson, and
A J Greenspon, and
D Shoshani, and
A M Greenspan
November 1985,
Harefuah,
H H Rotmensch, and
B N Swanson, and
A J Greenspon, and
D Shoshani, and
A M Greenspan
October 1980,
Journal of clinical pharmacology,
H H Rotmensch, and
B N Swanson, and
A J Greenspon, and
D Shoshani, and
A M Greenspan
October 1983,
American heart journal,
H H Rotmensch, and
B N Swanson, and
A J Greenspon, and
D Shoshani, and
A M Greenspan
May 1999,
The Annals of pharmacotherapy,
H H Rotmensch, and
B N Swanson, and
A J Greenspon, and
D Shoshani, and
A M Greenspan
January 2000,
Studies in health technology and informatics,
H H Rotmensch, and
B N Swanson, and
A J Greenspon, and
D Shoshani, and
A M Greenspan
March 1979,
American journal of hospital pharmacy,
H H Rotmensch, and
B N Swanson, and
A J Greenspon, and
D Shoshani, and
A M Greenspan
March 1986,
Klinische Wochenschrift,
H H Rotmensch, and
B N Swanson, and
A J Greenspon, and
D Shoshani, and
A M Greenspan
September 1984,
Drug intelligence & clinical pharmacy,
